NCT05195983

Brief Summary

  1. 1.To assess Hemodynamic changes in rtPA receiving Acute Ischaemic Stroke patients.
  2. 2.To assess the efficacy of rtPA in treatment of Acute Ischaemic Stroke patients.
  3. 3.To correlate TCD findings (post treatment) with one of standard vascular imaging in AIS (CTA or MRA).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 5, 2022

Completed
5 days until next milestone

Study Start

First participant enrolled

January 10, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 19, 2022

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

January 19, 2022

Status Verified

January 1, 2022

Enrollment Period

2.9 years

First QC Date

January 5, 2022

Last Update Submit

January 5, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Clinical outcomes 1-neurological outcomes

    assessed by NIHSS and comprising improvement (reduction of 10 points or final NIHSS ≤3) or deterioration (increase ≥4 points) in the early post-thrombolytic therapy stage

    7 days

  • 2-functional

    defined by modified Rankin scale (mRS) in the late post-thrombolytic therapy (2-3 months) with good outcome been considered as mRS ≤2 ,with sICH is defined as rtPA-related intracerebral bleeding detected by CT or MRI associated with any worsening of NIHSS or death.

    baseline

Secondary Outcomes (2)

  • Radiological outcome

    24 hours

  • laboratory outcome

    baseline

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all cases eligible for rtPA will be recruited .

You may qualify if:

  • age \> 18, both sexes, acute ischemic stroke within 4.5 hours, NIHSS (5-25)

You may not qualify if:

  • Significant head trauma or prior stroke in the previous 3 months
  • Symptoms suggest subarachnoid hemorrhage
  • Arterial puncture at a noncompressible site in previous 7 days
  • History of previous intracranial hemorrhage
  • Intracranial neoplasm, AVM, or an aneurysm
  • Recent intracranial or intraspinal surgery
  • Elevated blood pressure (systolic greater than 185 mmHg or diastolic greater than 110 mmHg)
  • Active internal bleeding
  • Acute bleeding diathesis, including but not limited to
  • Platelet count less than 100 000/mm\^3
  • Heparin received within 48 hours resulting in abnormally elevated aPTT above the upper limit of normal
  • Current use of anticoagulant with INR greater than 1.7 or PT greater than 15 seconds
  • Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (e.g., aPTT, INR, platelet count, ECT, TT, or appropriate factor Xa activity assays)
  • Blood glucose concentration less than 50 mg/dL (2.7 mmol/L)
  • Recent experience suggests that under some circumstances, with careful consideration and weighing of risk to benefit, patients may receive fibrinolytic therapy despite 1 or more relative contraindications. Consider the risk to the benefit of intravenous rtPA administration carefully if any of these relative contraindications are present:
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Arima H, Huang Y, Wang JG, Heeley E, Delcourt C, Parsons M, Li Q, Neal B, Chalmers J, Anderson C; INTERACT1 Investigators. Earlier blood pressure-lowering and greater attenuation of hematoma growth in acute intracerebral hemorrhage: INTERACT pilot phase. Stroke. 2012 Aug;43(8):2236-8. doi: 10.1161/STROKEAHA.112.651422. Epub 2012 Jun 7.

    PMID: 22678090BACKGROUND
  • Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007 Jun;38(6):1873-80. doi: 10.1161/STROKEAHA.106.474569. Epub 2007 Apr 19.

    PMID: 17446429BACKGROUND
  • Gerriets T, Goertler M, Stolz E, Postert T, Sliwka U, Schlachetzki F, Seidel G, Weber S, Kaps M. Feasibility and validity of transcranial duplex sonography in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2002 Jul;73(1):17-20. doi: 10.1136/jnnp.73.1.17.

    PMID: 12082039BACKGROUND
  • Mazya MV, Ahmed N, Azevedo E, Davalos A, Dorado L, Karlinski M, Lorenzano S, Neumann J, Toni D, Moreira TP; SITS Investigators. Impact of Transcranial Doppler Ultrasound on Logistics and Outcomes in Stroke Thrombolysis: Results From the SITS-ISTR. Stroke. 2018 Jul;49(7):1695-1700. doi: 10.1161/STROKEAHA.118.021485. Epub 2018 May 29.

    PMID: 29844031BACKGROUND
  • Zhang Z, Pu Y, Mi D, Liu L. Cerebral Hemodynamic Evaluation After Cerebral Recanalization Therapy for Acute Ischemic Stroke. Front Neurol. 2019 Jul 3;10:719. doi: 10.3389/fneur.2019.00719. eCollection 2019.

    PMID: 31333570BACKGROUND
  • Xu JH, He XW, Li Q, Liu JR, Zhuang MT, Huang FF, Bao GS. Higher Platelet-to-Lymphocyte Ratio Is Associated With Worse Outcomes After Intravenous Thrombolysis in Acute Ischaemic Stroke. Front Neurol. 2019 Nov 13;10:1192. doi: 10.3389/fneur.2019.01192. eCollection 2019.

    PMID: 31798520BACKGROUND
  • Wang C, Zhang Q, Ji M, Mang J, Xu Z. Prognostic value of the neutrophil-to-lymphocyte ratio in acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. BMC Neurol. 2021 May 11;21(1):191. doi: 10.1186/s12883-021-02222-8.

    PMID: 33975565BACKGROUND

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Mostafa A. Sedky, resident

CONTACT

Anwar M. Ali, professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident

Study Record Dates

First Submitted

January 5, 2022

First Posted

January 19, 2022

Study Start

January 10, 2022

Primary Completion

December 1, 2024

Study Completion

March 1, 2025

Last Updated

January 19, 2022

Record last verified: 2022-01